Scarica l'app Stockscreener
3.88
0.52%
0.02
Dopo l'orario di chiusura:
3.90
0.02
+0.52%
Precedente Chiudi:
$3.86
Aprire:
$3.9
Volume 24 ore:
80,738
Relative Volume:
1.80
Capitalizzazione di mercato:
$29.00M
Reddito:
$7.00M
Utile/perdita netta:
$-70.79M
Rapporto P/E:
-0.4004
EPS:
-9.69
Flusso di cassa netto:
$-64.34M
1 W Prestazione:
-0.51%
1M Prestazione:
-10.80%
6M Prestazione:
-38.41%
1 anno Prestazione:
-36.57%
Intervallo 1D:
$3.85
$3.94
Intervallo di 1 settimana:
$3.85
$4.0699
Portata 52W:
$3.6201
$9.18
Kezar Life Sciences Inc Stock (KZR) Company Profile
Nome
Kezar Life Sciences Inc
Settore
Industria
Telefono
650-822-5600
Indirizzo
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta KZR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
3.88 | 29.00M | 7.00M | -70.79M | -64.34M | -9.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.76 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.28 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.78 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
656.89 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.51 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Wells Fargo | Outperform |
| 2018-07-16 | Iniziato | William Blair | Outperform |
Mostra tutto
Kezar Life Sciences Inc Borsa (KZR) Ultime notizie
Short interest data insights for Kezar Life Sciences Inc.Market Risk Summary & Growth Focused Investment Plans - Newser
Forecasting Kezar Life Sciences Inc. price range with options dataJuly 2025 Big Picture & Safe Entry Momentum Tips - Newser
Should you wait for a breakout in Kezar Life Sciences Inc.Weekly Market Report & Daily Profit Maximizing Trade Tips - Newser
What does recent volatility data suggest for Kezar Life Sciences Inc.Weekly Market Summary & Reliable Breakout Stock Forecasts - Newser
Smart tools for monitoring Kezar Life Sciences Inc.’s price actionMarket Movement Recap & Real-Time Buy Zone Alerts - Newser
Is this a good reentry point in Kezar Life Sciences Inc.Earnings Trend Report & Weekly Return Optimization Alerts - Newser
What to do if you’re stuck in Kezar Life Sciences Inc.Earnings Overview Report & Real-Time Buy Zone Alerts - Newser
What earnings revisions data tells us about Kezar Life Sciences Inc.Quarterly Risk Review & Weekly Top Gainers Trade List - Newser
Is Kezar Life Sciences Inc. stock entering bullish territoryPortfolio Performance Report & Long-Term Investment Growth Plans - Newser
William Blair Brokers Boost Earnings Estimates for KZR - Defense World
Real time social sentiment graph for Kezar Life Sciences Inc.Quarterly Trade Report & Smart Swing Trading Techniques - Newser
Is Kezar Life Sciences Inc. stock reversal real or fakeQuarterly Portfolio Summary & Smart Allocation Stock Tips - Newser
Technical Bounce Expected in Kezar Life Sciences Inc. Next WeekMarket Performance Report & High Win Rate Trade Alerts - classian.co.kr
Main Inc. stock outlook for YEARJuly 2025 Volume & Comprehensive Market Scan Reports - Newser
What candlestick patterns are forming on Kezar Life Sciences Inc.July 2025 Levels & AI Based Buy and Sell Signals - Newser
How Kezar Life Sciences Inc. stock reacts to Fed policy changesTrade Performance Summary & Safe Swing Trade Setups - Newser
Is Kezar Life Sciences Inc. likely to announce a buybackJuly 2025 Big Picture & Fast Exit and Entry Strategy Plans - thegnnews.com
Kezar Life Sciences Inc. Recovery Likely Here’s What Data ShowsValue Driven Trading Forecast Strategy - beatles.ru
Wells Fargo Keeps Their Hold Rating on Kezar Life Sciences (KZR) - The Globe and Mail
Is it too late to sell Kezar Life Sciences Inc.Trend Reversal & Stepwise Trade Execution Plans - Newser
Should you hold or exit Kezar Life Sciences Inc. nowQuarterly Portfolio Report & Breakout Confirmation Trade Signals - Newser
What the charts say about Kezar Life Sciences Inc. todayMarket Activity Report & Daily Profit Maximizing Trade Tips - Newser
How to escape a deep drawdown in SoundHound AI Inc. Equity WarrantWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - Newser
Should you hold or exit Sprouts Farmers Market Inc. nowJuly 2025 Spike Watch & Capital Protection Trading Alerts - Newser
Using AI based signals to follow Arrowhead Pharmaceuticals Inc.Weekly Trading Summary & Fast Gaining Stock Reports - Newser
Detecting support and resistance levels for Kezar Life Sciences Inc.July 2025 Big Picture & High Return Stock Watch Alerts - Newser
Can technical indicators confirm Kezar Life Sciences Inc.’s reversalWeekly Earnings Recap & Accurate Intraday Trading Signals - Newser
How to use a screener to detect Kezar Life Sciences Inc. breakoutsJuly 2025 Patterns & Stock Market Timing Techniques - Newser
How Kezar Life Sciences Inc. stock performs during market volatilityMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Can Kezar Life Sciences Inc. ride the EV wave2025 Market Overview & High Accuracy Investment Entry Signals - sundaytimes.kr
Kezar Life Sciences' Positive Trial Results and Regulatory Progress Boost Buy Rating - AInvest
Positive Phase 2 Trial Results and Regulatory Progress Bolster Buy Rating for Kezar Life Sciences - TipRanks
Kezar Life Sciences Advances in Autoimmune Hepatitis Trials - TipRanks
Why Kezar Life Sciences Inc. stock attracts strong analyst attentionCEO Change & AI Driven Price Predictions - Newser
Published on: 2025-08-16 23:04:27 - Newser
Kezar Narrows Loss 37 Percent in Q2 - AOL.com
Kezar Life Sciences Q2 Earnings Exceed Expectations, Cash Reserves Down - AInvest
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - The Joplin Globe
Kezar Life Sciences Inc Azioni (KZR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kezar Life Sciences Inc Azioni (KZR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schiller Mark C. | Chief Operating Officer |
Jul 02 '25 |
Sale |
4.28 |
561 |
2,401 |
2,739 |
0.22%
3.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):